By Ariana Pelosci
Women with gynecologic cancer who experience an improvement of social needs such as companionship and food insecurity could experience improved outcomes.
The identification of social needs and accompanying solutions could result in more actionable health care disparities … Read more
DALLAS – July 30, 2021 – UT Southwestern faculty have discovered what appears to be an Achilles’ heel in ovarian cancers, as well as new biomarkers that could point to which patients are the best candidates for possible new treatments.… Read more
For a second time, researchers will test an antibiotic discovered in the 1950s as a potential treatment for cancer.
The first attempt to study the drug, novobiocin, in patients with cancer was a small clinical trial conducted 30 years ago. … Read more
Researchers at Texas A&M University are pushing organ-on-a-chip devices to new levels that could change the way clinicians approach cancer treatment, particularly ovarian cancer. A team has recently submitted a patent disclosure with the Texas A&M Engineering Experiment Station.… Read more
A new study published online today in the Journal of the National Cancer Institute reports that one third of the most popular cancer treatment articles on social media contain misinformation. Further, the vast majority of that misinformation has the potential … Read more
The combination of ceralasertib and olaparib induced clinical activity and was well tolerated in patients with homologous recombination deficient, recurrent platinum-sensitive, PARP inhibitor–resistant ovarian cancer.
The combination of ceralasertib and olaparib (Lynparza) induced clinical activity and was well tolerated in … Read more
By Ariana Pelosci
A new phase 2 study shows that patients who were treated with HIPEC and Carboplatin, did not have better progression-free or overall survival.
Although hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin appeared to be well tolerated in patients … Read more
CAMBRIDGE, England — Virtual biopsies could replace invasive tissue procedures and give more accurate results thanks to a revolutionary new method developed using computer scans. The new advanced computing technique uses routine medical scans to enable doctors to take fewer, … Read more
By Alan Mozes
Could a new one-and-done blood test designed to detect as many as 50 different types of cancer become a diagnostic game changer?
Yes, say researchers, who report the method appears accurate and reliable at identifying and locating … Read more
Studies in laboratory cell lines and in mouse tumor models show an antibiotic developed in the 1950s called novabiocin effectively targets and kills cancer cells with abnormal BRCA1 or BRCA2 genes, which normally help to repair damaged DNA.… Read more
By Mike Bassett
Dampened responses seen in those with hematological malignancies, however patients with cancer who were vaccinated against COVID-19 achieved high seroconversion rates, a single-center study found.
The rate of seroconversion was especially high among patients with solid tumors … Read more
A novel vaccine appeared safe and demonstrated clinical benefit as front-line maintenance therapy for women with advanced-stage ovarian cancer, according to results of a phase 2b trial presented during the virtual ASCO Annual Meeting.… Read more
Rates of genetic testing in ovarian cancer “remain well below the goal of universal testing,” according to authors of a systematic review and meta-analysis published in Gynecologic Oncology.1… Read more
Experts reveal pafolacianine sodium may offer a novel real-time adjunct to current surgical imaging practice in ovarian cancer surgery, according to a phase 3 study being presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.… Read more
The combination of mirvetuximab soravtansine and bevacizumab produces “impressive antitumor activity” in patients with recurrent ovarian cancer and high folate receptor alpha (FRα) expression, according to researchers.… Read more
Doubling treatment duration of bevacizumab did not lead to better survival in patients with ovarian cancer who were treated on a phase 3 trial.
For patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, prolonged treatment
An odor-based test that detects vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95% accuracy, according to a new study presented by Johnson et al during the 2021 … Read more
Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with … Read more
In an MSK Team Ovary–led phase II trial reported in the Journal of Clinical Oncology, Zivanovic et al found that use of hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin during secondary cytoreduction followed by chemotherapy did not improve 24-month progression-free … Read more
In a prospective study in Israel, 90% of cancer patients were seropositive for antibodies
By Mike Bassett
The vast majority of patients undergoing active systemic therapy for cancer exhibited an adequate immune response to the Pfizer/BioNTech COVID-19 vaccine, according to … Read more
